Prepare for your visit

Karen Roden

Nurse Practitioner · Knoxville, TN · NPI 1225023781

One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.

What was reported

$264,937.23

in general payments reported to CMS, 2019-2025 · $68K in 2025

The $68K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).

Who reported paying

General payments only, top 6 by amount.

Astrazeneca Pharmaceuticals LP $158,432.43
Genentech USA, INC. $49,531.28
Genzyme Corporation $20,206.73
Regeneron Healthcare Solutions, INC. $18,249.41
Amgen INC. $11,708.25
Novartis Pharmaceuticals Corporation $957.14

Drugs and devices associated with these payments

Airsupra Tezspire Xolair Dupixent Fasenra Xhance Hizentra Myrisk Trelegy Ellipta Enhertu Nucala Neffy

Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.

Questions you might ask

I saw Karen Roden listed in the CMS Open Payments database. Can you tell me about your work with those companies?
Is there a generic or alternative to this medication, and would it work as well for me?
What made you choose this particular treatment for my situation?

These are normal questions. A good clinician will welcome them.

Notes

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.

GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/10967467/karen-roden